RSV Shot Beyfortus Faces Shortage Amid Increasing Demand; CDC Advises Priority for High-Risk Infants
Sanofi's newly launched respiratory syncytial virus (RSV) preventative drug, Beyfortus, experiences supply shortage due to "unprecedented demand", leading the CDC to recommend priority use for highest-risk infants. The unavailability of the treatment is compounded by issues with the US childhood vaccination system and concerns surrounding insurance reimbursement.
